Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: Conference

Tricida Announces that 2020 Annual Meeting Will be Held in Virtual Format


Tricida, Inc. (Nasdaq: TCDA) announced that, due to public health concerns relating to the coronavirus pandemic (COVID-19) and to protect the health of its employees, directors and stockholders, its 2020 annual meeting of stockholders (the "Annual Meeting") will be held in a virtual-only format.

The previously announced date and time of the Annual Meeting, Thursday, June 11, 2020 at 7:00 a.m. Pacific Daylight Time, will not change, but stockholders will not be able to attend in person. The virtual meeting will provide stockholders with the ability to vote their shares during the meeting and ask questions online. To gain access to the Annual Meeting, stockholders must go to the meeting website at www.virtualstockholdermeeting.com/TCDA2020.

As described in the proxy materials for the Annual Meeting previously distributed, stockholders as of the close of business on April 15, 2020, the record date, are entitled to participate in the Annual Meeting. To participate, stockholders will need the 16-digit control number included in the proxy materials delivered to such stockholder.

A notice regarding the change of location of the Annual Meeting (the "Notice") is being filed with the Securities and Exchange Commission together with this press release. Additional information regarding the Annual Meeting, stockholder participation and voting is provided in the Notice.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States. Tricida is currently conducting its confirmatory postmarketing trial, VALOR-CKD, of veverimer. The Tricida New Drug Application (NDA) for veverimer has been accepted for review by the U.S. Food and Drug Administration (FDA) through the Accelerated Approval Program. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 22, 2020.

For more information about Tricida, please visit www.Tricida.com.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements, including for example, statements about the assigned PDUFA goal date of August 22, 2020, and the potential availability of the Accelerated Approval Program. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, that we may not be able to achieve upcoming milestones; the cost, timing and results of clinical trials and other studies; that many drug candidates that have completed Phase 3 trials do not become approved drugs on a timely or cost effective basis or at all; there can be no assurance that the FDA would approve an NDA through the Accelerated Approval Program, or at all, and even if approval for a drug is obtained, there can be no assurance that it will be adopted in the market or accepted as a benefit to patients and healthcare providers; possible safety and efficacy concerns; the impact of COVID-19; and that we completely rely on third-party suppliers and manufacturers for many aspects of our business. These and other factors that may affect our future results of operations are identified and described in more detail in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect Tricida's current views with respect to future events, and Tricida does not undertake and specifically disclaims any obligation to update any forward-looking statements.


These press releases may also interest you

at 20:05
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2020 on Thursday, July 30, 2020, following the close of the market. The company will discuss...

at 19:32
On behalf of the American BioDefense Institute, we commend Rep. Paul Gosar of Arizona on proposing an amendment to the H.R.6395 - William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021. We submit this statement for the...

at 19:01
In lieu of an in-person update to the media, Dr. Howard Njoo, Canada's Deputy Chief Public Health Officer, issued the following statement on behalf of Dr. Theresa Tam, Canada's Chief Public Health Officer. "There have been 108,486 cases of COVID-19...

at 18:57
Neptune Wellness Solutions Inc. ("NEPT" or the "Company") , a diversified and fully integrated health and wellness company focused on natural, plant-based, sustainable and purpose-driven lifestyle brands, today announced it has closed its...

at 18:26
New projections released today by PolicyLab at Children's Hospital of Philadelphia (CHOP) forecast a continued surge in COVID-19 cases over the next four weeks in many areas of the country, with renewed risk spreading into the Northeast and Midwest,...

at 18:12
Mallinckrodt plc , a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted to recommend approval for its investigational agent terlipressin to...



News published on 3 june 2020 at 16:40 and distributed by: